Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Lnp.ucd.abe

Preclinical

RRebecca Ahrens-Nicklas

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Urea Cycle DisordersNot yet recruiting

Urea Cycle DisordersPreclinical

Not yet recruiting

Timeline

Expected Milestones

Q3 2028

PreclinicalNot yet recruiting

Urea Cycle Disorders

NCT07667387

Clinical

Trials by Indication[1]

Urea Cycle Disorders1 trial

Master Protocol for a Phase I/II Open-label Safety and Efficacy Study of LNP.UCD.ABE, a Lipid Nanoparticle-delivered Base Editing Therapy, in Patients With Urea Cycle Disorders Due to Variants Amenable to Corrective Editing by LNP.UCD.ABE

Not yet recruiting·RRebecca Ahrens-Nicklas·Preclinical·NCT07667387·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lnp.ucd.abe. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Lnp.ucd.abe. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Rebecca Ahrens-Nicklas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: RRebecca Ahrens-Nicklas

Related News